LL-37: Handling, Storage, and Reconstitution Guide

This guide covers laboratory handling, storage, and reconstitution of LL-37, the human cathelicidin antimicrobial peptide, as a lyophilized research material. Every step below is framed as laboratory best practice for in-vitro and animal-model preparation, not as human-use instruction.

LL-37 Handling and Storage Fundamentals

LL-37 ships as a solid, white lyophilized powder in a sealed glass vial. Store the lyophilized material at or below 25 degrees Celsius, sealed, and protected from heat, light, and moisture. For extended storage, keep it lyophilized and refrigerated or frozen. As a large peptide, LL-37 benefits from careful cold-chain discipline to preserve conformational integrity.

Puritide supplies LL-37 in a 5 mg vial, so working-stock concentration follows from the diluent volume chosen for that mass.

LL-37's size and conformational sensitivity make handling somewhat more demanding than for short fragments. Gentle reconstitution and attention to buffer conditions matter more here, because the peptide's behavior in downstream assays is tied to its conformation, which the preparation environment can influence. Investigators often decide the reconstitution solvent in advance based on the intended assay, since the choice of water versus a defined buffer can shape how the peptide presents to microbial or host membranes in the experiments that follow.

Confirm Identity Before Use

Verify the material against its documentation: molecular formula C205H340N60O53, molecular weight approximately 4493.33 g/mol, and CAS number 154947-66-7, with synonyms including cathelicidin LL-37 and hCAP18 (134-170). Matching these to the certificate of analysis is the first traceability checkpoint and anchors the membrane and immunomodulation assays in the LL-37 mechanism of action.

Reconstitution for In-Vitro Preparation

Reconstitute lyophilized LL-37 with a solvent appropriate to the assay; bacteriostatic water or a suitable buffer is common for in-vitro prep. Add the diluent slowly down the inner wall of the vial rather than onto the powder, and allow the peptide to dissolve gently. Swirl; avoid vortexing aggressively or shaking, which can shear the peptide.

• Introduce diluent against the vial wall, not onto the pellet.
• Allow gentle, complete dissolution of this larger peptide.
• Note that buffer and ionic conditions can affect activity.
• Compute concentration from labeled mass and diluent volume.

Buffer and Ionic Considerations

Because LL-37 is cationic and conformation-sensitive, its membrane behavior can depend on buffer composition and ionic strength. Choose and document assay conditions carefully so results are reproducible. This handling nuance directly supports the antimicrobial designs in the LL-37 research applications.

Aliquoting and Cold-Chain Storage

Divide reconstituted LL-37 into single-use aliquots to limit freeze-thaw, labeling each with compound name, concentration, date, and lot number. Store aliquots frozen for longer holds, and keep working solutions cold and protected from light. Maintain consistent conditions throughout the study and monitor storage records, mirroring the KPV handling guide and the ARA-290 handling guide.

COA and Lot Verification

Each LL-37 batch ships with a third-party-verified certificate of analysis documenting purity (HPLC / reverse-phase chromatography), mass-spectrometry identity confirmation, and lot, testing date, and method details. Verify the COA against the vial label and retain it with your batch records. Sample COAs can be requested ahead of purchase.

PPE and Institutional Compliance

Handle LL-37 as an investigational material. Follow institutional SOPs, chemical hygiene plans, and approved protocols; wear a lab coat, gloves, and eye protection; and use engineering controls where required. All handling should be performed by qualified personnel in controlled environments. Specifications are on the LL-37 product page.

At intake, match the vial to its recorded synonyms, including cathelicidin LL-37 and hCAP18 (134-170), and confirm the expected white lyophilized appearance. Because LL-37's activity depends on its environment, pairing intake verification with careful documentation of buffer conditions gives later teams the full context needed to reproduce a result.

Recording Buffer and Assay Conditions

For LL-37, preparation documentation should extend beyond the vial to the assay environment, because buffer composition and ionic strength influence the peptide's behavior. Recording the reconstitution solvent, any assay buffer, and the ionic conditions alongside the lot number and certificate of analysis gives a complete account of the factors that shape an LL-37 result.

This is particularly important for antimicrobial designs, where salt concentration can attenuate activity. Logging these conditions lets a later team reproduce not just the material but the environment in which it was tested, which for a context-dependent peptide like LL-37 is essential to reproducibility.

Consistent handling is ultimately a reproducibility measure. A LL-37 preparation that is verified against its certificate of analysis, reconstituted gently, aliquoted to limit freeze-thaw, stored under stable cold-chain conditions, and fully documented gives every downstream experiment the same reliable starting material. That consistency is what allows independent laboratories to compare results and build on one another's work with confidence. When a study later proves difficult to reproduce, a complete handling record is often what lets investigators distinguish a genuine biological difference from a preparation artifact, which is why the effort invested in disciplined LL-37 handling repays itself throughout a project.

For research use only. These handling notes describe laboratory practice for LL-37 as a research material supplied by Puritide Research. LL-37 is not approved for human or veterinary use, and nothing here constitutes medical or administration guidance.